Qiagen N.V. (QGEN) Stock Analysis
Recovery setup
Healthcare · Diagnostics & Research
Hold if already holding. Not a fresh buy at $34.27, but acceptable to hold if already in. Reasons: Weak growth; Below 200-MA, MA slope -3.0%/30d (confirmed downtrend).
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing... Read more
Hold if already holding. Not a fresh buy at $34.27, but acceptable to hold if already in. Reasons: Weak growth; Below 200-MA, MA slope -3.0%/30d (confirmed downtrend). Chart setup: Death cross but MACD improving, RSI 49. Maintain position. Not compelling to add more. Score 5.2/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 77d clear, semi cycle peak clear, materials cycle peak clear). Suitability: moderate.
Recent Developments — Qiagen N.V.
Latest news
- JPMorgan Chase & Co. Has Lowered Expectations for Qiagen (NYSE:QGEN) Stock Price - MarketBeat — MarketBeat negative
- Citigroup Lowers Qiagen (NYSE:QGEN) Price Target to $38.00 - MarketBeat — MarketBeat negative
- Qiagen Sets Date for Publication of 2025 Annual Financial Report - The Globe and Mail — The Globe and Mail neutral
- Qiagen (NYSE:QGEN) Sets New 12-Month Low - Should You Sell? - MarketBeat — MarketBeat negative
- Is Qiagen NV (QGEN) a Bargain After 10.7% Drop? GF Value Says Un - GuruFocus — GuruFocus negative
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Analyst Consensus
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $34.27, but acceptable to hold if already in. Reasons: Weak growth; Below 200-MA, MA slope -3.0%/30d (confirmed downtrend). Chart setup: Death cross but MACD improving, RSI 49. Maintain position. Not compelling to add more. Target $38.12 (+11.2%), stop $31.92 (−7.4%), A.R:R 2.4:1. Score 5.2/10, moderate confidence.
Take-profit target: $38.12 (+12.8% upside). Target $38.12 (+11.2%), stop $31.92 (−7.4%), A.R:R 2.4:1. Stop-loss: $31.92.
Weak growth; Below 200-MA, MA slope -3.0%/30d (confirmed downtrend).
Qiagen N.V. trades at a P/E of 17.2 (forward 12.8). TrendMatrix value score: 7.3/10. Verdict: Hold.
24 analysts cover QGEN with a consensus score of 3.7/5. Average price target: $44.
What does Qiagen N.V. do?Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide....
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.